drug · small molecule
tiratricol ODT
pre_registrationupdated 5mo agoby Egetis Therapeutics AB🔗 ChEMBL
community read0 votes
Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for thyrotoxicosis and 3 investigational indications.
targets
Thyroid hormone receptor
all catalysts(0)
nothing on the calendar yet
Trials studying tiratricol ODT
News(3)
- Egetis Therapeutics' Emcitate cleared by FDA for rare X-linked genetic diseaseEgetis Therapeutics has secured US approval of its drug for a rare disease that shortens life expectancy to 35 years. The FDA on Monday backed tiratricol for certain patients with monocarboxylate ...endpoints · 6d ago
- Recon: FDA approves Egetis’ Emcitate for rare genetic disease; Novo buys rights to Chinese weight-loss pill in $2.6B dealWelcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.raps · 6d ago
- FDA Approves First Treatment for MCT8 DeficiencyThe U.S. Food and Drug Administration today approved Emcitate (tiratricol) tablets for oral suspension to treat peripheral thyrotoxicosis (excess thyroid hormone levels in the blood that causes sym…fda_press · 6d ago
Data sources
last refreshed 3h ago
Found something off?
comments(0)
5-min edit window · permanent after that